Biotechnology
Compare Stocks
2 / 10Stock Comparison
JAGX vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
JAGX vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $188K | $1.69B |
| Revenue (TTM) | $12M | $4.18B |
| Net Income (TTM) | $-54M | $-1.82B |
| Gross Margin | 67.2% | 34.2% |
| Operating Margin | -398.8% | -4.1% |
| Forward P/E | — | 5.8x |
| Total Debt | $44M | $3.97B |
| Cash & Equiv. | $968K | $532M |
JAGX vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 100 | 0.0 | -100.0% |
| Perrigo Company plc (PRGO) | 100 | 22.4 | -77.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JAGX vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
JAGX is the clearest fit if your priority is growth exposure.
- Rev growth -1.5%, EPS growth 82.4%, 3Y rev CAGR -1.3%
- -1.5% revenue growth vs PRGO's -2.8%
- Better valuation composite
PRGO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 10 yrs, beta 1.18, yield 9.4%
- -76.8% 10Y total return vs JAGX's -100.0%
- Lower volatility, beta 1.18, current ratio 2.76x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -1.5% revenue growth vs PRGO's -2.8% | |
| Value | Better valuation composite | |
| Quality / Margins | -43.5% margin vs JAGX's -465.4% | |
| Stability / Safety | Beta 1.18 vs JAGX's 2.72 | |
| Dividends | 9.4% yield; 10-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -45.6% vs JAGX's -99.3% | |
| Efficiency (ROA) | -19.8% ROA vs JAGX's -114.3%, ROIC 3.7% vs -116.8% |
JAGX vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
JAGX vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
PRGO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 363.0x JAGX's $12M. Profitability is closely matched — net margins range from -43.5% (PRGO) to -4.7% (JAGX).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $12M | $4.2B |
| EBITDAEarnings before interest/tax | -$54M | $58M |
| Net IncomeAfter-tax profit | -$54M | -$1.8B |
| Free Cash FlowCash after capex | -$24M | $108M |
| Gross MarginGross profit ÷ Revenue | +67.2% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -4.0% | -4.1% |
| Net MarginNet income ÷ Revenue | -4.7% | -43.5% |
| FCF MarginFCF ÷ Revenue | -2.1% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.8% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +90.1% | -56.4% |
Valuation Metrics
JAGX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $187,925 | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $43M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -1.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.82x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.53x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 0.40x |
| Price / BookPrice ÷ Book value/share | — | 0.58x |
| Price / FCFMarket cap ÷ FCF | 0.03x | 11.63x |
Profitability & Efficiency
PRGO leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), PRGO scores 4/9 vs JAGX's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -50.7% |
| ROA (TTM)Return on assets | -114.3% | -19.8% |
| ROICReturn on invested capital | -116.8% | +3.7% |
| ROCEReturn on capital employed | -2.9% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 1.35x |
| Net DebtTotal debt minus cash | $43M | $3.4B |
| Cash & Equiv.Liquid assets | $968,000 | $532M |
| Total DebtShort + long-term debt | $44M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -565.60x | -7.20x |
Total Returns (Dividends Reinvested)
PRGO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRGO five years ago would be worth $4,142 today (with dividends reinvested), compared to $0 for JAGX. Over the past 12 months, PRGO leads with a -45.6% total return vs JAGX's -99.3%. The 3-year compound annual growth rate (CAGR) favors PRGO at -24.3% vs JAGX's -94.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -91.9% | -9.6% |
| 1-Year ReturnPast 12 months | -99.3% | -45.6% |
| 3-Year ReturnCumulative with dividends | -100.0% | -56.6% |
| 5-Year ReturnCumulative with dividends | -100.0% | -58.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | -76.8% |
| CAGR (3Y)Annualised 3-year return | -94.0% | -24.3% |
Risk & Volatility
PRGO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than JAGX's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRGO currently trades 43.1% from its 52-week high vs JAGX's 0.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.72x | 1.18x |
| 52-Week HighHighest price in past year | $423.15 | $28.44 |
| 52-Week LowLowest price in past year | $0.71 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +0.7% | +43.1% |
| RSI (14)Momentum oscillator 0–100 | 17.0 | 53.7 |
| Avg Volume (50D)Average daily shares traded | 36K | 3.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
PRGO is the only dividend payer here at 9.38% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $20.00 |
| # AnalystsCovering analysts | — | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.4% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
PRGO leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). JAGX leads in 1 (Valuation Metrics).
JAGX vs PRGO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is JAGX or PRGO a better buy right now?
For growth investors, Jaguar Health, Inc.
(JAGX) is the stronger pick with -1. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Analysts rate Perrigo Company plc (PRGO) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — JAGX or PRGO?
Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -58.
6%, compared to -100. 0% for Jaguar Health, Inc. (JAGX). Over 10 years, the gap is even starker: PRGO returned -76. 8% versus JAGX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — JAGX or PRGO?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
18β versus Jaguar Health, Inc. 's 2. 72β — meaning JAGX is approximately 130% more volatile than PRGO relative to the S&P 500.
04Which is growing faster — JAGX or PRGO?
By revenue growth (latest reported year), Jaguar Health, Inc.
(JAGX) is pulling ahead at -1. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Jaguar Health, Inc. grew EPS 82. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, JAGX leads at -1. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — JAGX or PRGO?
Perrigo Company plc (PRGO) is the more profitable company, earning -33.
5% net margin versus -465. 4% for Jaguar Health, Inc. — meaning it keeps -33. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -398. 8% for JAGX. At the gross margin level — before operating expenses — JAGX leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — JAGX or PRGO?
In this comparison, PRGO (9.
4% yield) pays a dividend. JAGX does not pay a meaningful dividend and should not be held primarily for income.
07Is JAGX or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 4% yield). Jaguar Health, Inc. (JAGX) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -76. 8%, JAGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between JAGX and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: JAGX is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while JAGX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.